When T-cell bispecific antibodies (bsAbs) became available for relapsed or refractory multiple myeloma several years ago, Yazhini Vallatharasu, MD, wanted her patients at ThedaCare Cancer Center, a community center in Appleton, Wisconsin, to have access to the rapidly expanding number of therapies, including teclistamab (Tecvayli) and elranatamab (Elrexfio). However, these bsAbs are primarily offered at academic medical centers.